The tricyclic antidepressant clomipramine increases plasma glucose levels of mice.
Effects of the tricyclic antidepressant clomipramine on plasma glucose levels in mice were studied. Clomipramine at doses ranging 5 - 20 mg/kg elicited significant hyperglycemia in mice. Hyperglycemia elicited by clomipramine was not reduced by pretreatment with the 5-hydroxytryptamine (5-HT) depleter p-chlorophenylalanine. The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it. The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect. Clomipramine-induced hyperglycemia was reduced by prior adrenalectomy. These results suggest that clomipramine induces hyperglycemia in mice by blocking the 5-HT(2B )and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.
D000315:Adrenalectomy; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism*; D002997:Clomipramine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006943:Hyperglycemia / Q000097:blood* / Q000503:physiopathology; D008297:Male; D051379:Mice; D018490:Serotonin Agents / Q000494:pharmacology
D000929:Antidepressive Agents, Tricyclic; D001786:Blood Glucose; D018490:Serotonin Agents; D002997:Clomipramine